New circulating biomarkers for prostate cancer

Bensalah, Karim; Lotan, Yair; Karam, Jose A.; Shariat, Shahrokh F.

doi:10.1038/sj.pcan.4501026

Cited by 63 publications

(38 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies have shown that IGFBP2 is overexpressed in glioma, prostate, and breast cancers (Kanety et al 1993;Busund et al 2005;Lin et al 2009). In prostate cancer, serum levels of IGFBP2 can be measured and levels increase as the cancer progresses (Shariat et al 2002;Bensalah et al 2008). IL-6, a cytokine that can be both pro-and antiinflammatory, plays an important role in the metastasis of prostate cancer (Shariat et al 2002).…”

Section: Discussionmentioning

confidence: 99%

Noncoding RNAs that associate with YB-1 alter proliferation in prostate cancer cells

Liu

Arango-Argoty

et al. 2015

RNA

View full text Add to dashboard Cite

The highly conserved, multifunctional YB-1 is a powerful breast cancer prognostic indicator. We report on a pervasive role for YB-1 in which it associates with thousands of nonpolyadenylated short RNAs (shyRNAs) that are further processed into small RNAs (smyRNAs). Many of these RNAs have previously been identified as functional noncoding RNAs (http://www.johnlab.org/YB1). We identified a novel, abundant, 3′ -modified short RNA antisense to Dicer1 (Shad1) that colocalizes with YB-1 to P-bodies and stress granules. The expression of Shad1 was shown to correlate with that of YB-1 and whose inhibition leads to an increase in cell proliferation. Additionally, Shad1 influences the expression of additional prognostic markers of cancer progression such as DLX2 and IGFBP2. We propose that the examination of these noncoding RNAs could lead to better understanding of prostate cancer progression.

show abstract

Section: Discussionmentioning

confidence: 99%

Noncoding RNAs that associate with YB-1 alter proliferation in prostate cancer cells

Liu

Arango-Argoty

et al. 2015

RNA

View full text Add to dashboard Cite

show abstract

“…These factors have resulted in early detection and increased incidence of the disease (Bensalah et al, 2008). Radical prostatectomy is the gold standard for the treatment of clinical localized PCa.…”

Section: Introductionmentioning

confidence: 99%

Clinical and Pathological Parameters Predicting Extracapsular Disease in Patients Undergoing a Radical Prostatectomy for Clinically Localized Prostate Cancer

Sfoungaristos

Perimenis

2012

Prague Med. Rep.

View full text Add to dashboard Cite

show abstract

“…For example, elevated levels of PSA can reflect the presence of malignant cells but can also be related to non-malignant prostate disorders like benign prostatic hyperplasia (BPH), infection or chronic inflammations. [8] Increased serum PSA levels have been seen in patients with PCa, as well as in BPH and prostatitis, producing a high rate of false-positive cases. There also remains a wide overlap between PCa and BPH, particularly in patients with marginally increased PSA concentrations, in the range of 4-10 ng/mL, a range which is said to be a "grey zone" where there is a dilemma in differentiation between benign and malignant prostatic diseases; this dilemma has strengthened the necessity to improve PCa specificity by developing, combining and validating other diagnostic biomarkers with consideration of the sensitivity.…”

Section: Introductionmentioning

confidence: 99%

“…[23,24] Therefore, research has been dedicated to its prognostic and diagnostic importance, but with little supporting evidence for its use beyond common screening methods. [8] Several studies have reported that elevated CgA concentrations are associated with high-grade and advanced stage PCa. Some studies have indicated that increased serum CgA exceeded PSA increase as a marker of progression to hormone-refractory disease.…”

Section: Introductionmentioning

confidence: 99%

Combination of insulin-like growth factor-1, IGF binding protein-3, chromogranin A and prostate specific antigen can improve the detection of prostate cancer

Saleh¹,

Adly²,

Nassir³

2017

JCMT

View full text Add to dashboard Cite

Aim: Prostate cancer (PCa) is the second most prevalent male cancer worldwide and designated the sixth most frequent male cancer in Arab countries. Although prostate specific antigen (PSA) has become the best and most valuable biomarker for screening of PCa, elevated levels of PSA can reflect the presence of malignant cells but can overlap with benign prostatic diseases. There is a necessity to develop and improve current tools for early detection and diagnosis of PCa. This study was done to evaluate the validation of serum insulin-like growth factor-1 (IGF-1), IGF binding protein-3 (IGFBP-3), chromogranin A (CgA) and combination with PSA in treatment of benign prostatic hyperplasia (BPH) and PCa patients. Methods: The study included 72 patients with PCa, 70 BPH patients and 56 healthy male subjects of matched age. Full history and clinical data were recorded for all subjects. Results: Serum PSA attained sensitivity of 84% at 82% specificity with an accuracy of 83%, although IGF-1, IGFBP-3 and CgA did not recognize PCa patients. Conclusion: Combinations of IGF-1 and IGFBP-3 biomarkers with PSA were effectively differentiated between PCa and control groups as well as improving the overall value of sensitivity, specificity and diagnostic accuracy of PCa to 85% and 86% for IGF-1/PSA and IGFP-3/PSA respectively. Key words:Prostate cancer, benign prostatic hyperplasia, insulin-like growth factor-1, IGF binding protein-3, chromogranin A ABSTRACTArticle history:

show abstract

New circulating biomarkers for prostate cancer

Cited by 63 publications

References 111 publications

Noncoding RNAs that associate with YB-1 alter proliferation in prostate cancer cells

Noncoding RNAs that associate with YB-1 alter proliferation in prostate cancer cells

Clinical and Pathological Parameters Predicting Extracapsular Disease in Patients Undergoing a Radical Prostatectomy for Clinically Localized Prostate Cancer

Combination of insulin-like growth factor-1, IGF binding protein-3, chromogranin A and prostate specific antigen can improve the detection of prostate cancer

Contact Info

Product

Resources

About